专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

EP3858365A1 GOLD OPTIMIZED CAR T-CELLS 有权转让
公开(公告)号：EP3858365A1
公开(公告)日：2021-08-04
申请号：EP21157792.9
申请日：2017-08-31
申请人： Chimera Bioengineering Inc. , Wang, Benjamin , Zeiner, Gusti
发明人： WANG, Benjamin , ZEINER, Gusti
IPC分类号： A61K35/17 , A61K35/28 , A61K39/00 , A61K39/395 , C12N5/00
摘要： The present invention relates to a method of controlling a transgene, comprising the steps of obtaining a primary T-cell comprising a chimeric antigen receptor, and a heterologous nucleic acid comprising a polynucleotide encoding the transgene that is operably linked to a polynucleotide encoding a RNA degradation element (RDE), wherein the RDE is an AU rich element, wherein the heterologous nucleic acid is transcribed to make a transcript encoding the transgene operably linked to the RDE; exposing the primary T-cell to a ligand for the chimeric antigen receptor wherein binding of the ligand by the chimeric antigen receptor activates the primary T-cell and thereby changes a metabolic state of the primary T-cell; and expressing the transgene wherein the amount of polypeptide made from the transgene is increased after the change in metabolic state of the primary T-cell.

2. 发明申请

WO2019160815A1 COORDINATING GENE EXPRESSION USING RNA DESTABILIZING ELEMENTS 审中-公开
公开(公告)号：WO2019160815A1
公开(公告)日：2019-08-22
申请号：PCT/US2019/017503
申请日：2019-02-11
申请人： CHIMERA BIOENGINEERING, INC. , WANG, Benjamin , ZEINER, Gusti , MCNALLY, Krista
发明人： WANG, Benjamin , ZEINER, Gusti , MCNALLY, Krista
IPC分类号： A61K35/17 , C12N15/85
摘要： Control Devices are disclosed including RNA destabilizing elements (RDE), and RNA control devices, combined with transgenes, including Chimeric Antigen Receptors (CARs) in eukaryotic cells. RDEs can be combined with RNA control devices to make RDEs that include ligand mediated control. These smart RDEs and other RDEs can be used to optimize expression of transgenes, e.g., CARs, in the eukaryotic cells so that, for example, effector function is optimized. CARs and transgene payloads can also be engineered into eukaryotic cells so that the transgene payload is expressed and delivered at desired times from the eukaryotic cell.

3. 发明申请

WO2018045177A1 GOLD OPTIMIZED CAR T-CELLS 审中-公开
标题翻译：金优化汽车T细胞
公开(公告)号：WO2018045177A1
公开(公告)日：2018-03-08
申请号：PCT/US2017/049628
申请日：2017-08-31
申请人： CHIMERA BIOENGINEERING, INC. , WANG, Benjamin , ZEINER, Gusti
发明人： WANG, Benjamin , ZEINER, Gusti
IPC分类号： A61K35/17 , A61K35/28 , A61K39/00 , A61K39/395 , C12N5/00
摘要： Control Devices are disclosed including RNA destabilizing elements (RDE), RNA control devices, and destabilizing elements (DE) combined with Chimeric Antigen Receptors (CARs) or other transgenes in eukaryotic cells. Multicistronic vectors are also disclosed for use in engineering host eukaryotic cells with the CARs and transgenes under the control of the control devices. These control devices can be used to optimize expression of CARs in the eukaryotic cells so that, for example, effector function is optimized. CARs and transgene payloads can also be engineered into eukaryotic cells so that the transgene payload is expressed and delivered after stimulation of the CAR on the eukaryotic cell.
摘要翻译：在真核细胞中公开了控制装置，包括RNA失稳元件（RDE），RNA控制装置和与嵌合抗原受体（CAR）或其他转基因组合的去稳定元件（DE）。还公开了多顺反子载体用于在控制装置的控制下用CAR和转基因工程宿主真核细胞。这些控制装置可用于优化真核细胞中CAR的表达，以便例如效应功能得到优化。 CARs和转基因有效载荷也可以被工程化为真核细胞，从而转基因有效载荷在CAR在真核细胞上被刺激后被表达和递送。

4. 发明公开

EP3506916A1 GOLD OPTIMIZED CAR T-CELLS 有权转让
公开(公告)号：EP3506916A1
公开(公告)日：2019-07-10
申请号：EP17847552.1
申请日：2017-08-31
申请人： Chimera Bioengineering Inc. , Wang, Benjamin , Zeiner, Gusti
发明人： WANG, Benjamin , ZEINER, Gusti
IPC分类号： A61K35/17 , A61K35/28 , A61K39/00 , A61K39/395 , C12N5/00

5. 发明申请

WO2022125392A1 COMPOSITIONS AND METHODS FOR ACTIVATING T-CELLS 审中-公开
公开(公告)号：WO2022125392A1
公开(公告)日：2022-06-16
申请号：PCT/US2021/061781
申请日：2021-12-03
申请人： CHIMERA BIOENGINEERING, INC. [US]/[US]
发明人： WANG, Benjamin , ZEINER, Gusti
IPC分类号： A61K35/17 , C12N5/00
摘要： Methods and compositions for reducing Notch inhibition of T-cell activation are disclosed. Also, disclosed are RDEs which can be used to optimize expression of transgenes, e.g., CARs, in a eukaryotic cells so that, for example, effector function is optimized. CARs and transgene payloads can also be engineered into eukaryotic cells so that the transgene payload is expressed and delivered at desired times from the eukaryotic cell. Such CAR T-cells with transgene payloads can be combined with the administration of other molecules, e.g., other therapeutics such as anti cancer therapies.

6. 发明申请

WO2017100176A1 SMART CAR DEVICES AND DE CAR POLYPEPTIDES FOR TREATING DISEASE AND METHODS OF ENHANCING IMMUNE RESPONSES 审中-公开
标题翻译：用于治疗疾病的智能车装置和DE CAR多肽以及增强免疫应答的方法
公开(公告)号：WO2017100176A1
公开(公告)日：2017-06-15
申请号：PCT/US2016/065116
申请日：2016-12-06
申请人： CHIMERA BIOENGINEERING, INC.
发明人： WANG, Benjamin , ZEINER, Gusti
IPC分类号： A61K39/00 , C07K14/705 , C07K16/28 , C12N5/00
CPC分类号： A61K35/17 , A61K35/28 , A61K39/3955 , A61K39/39558 , A61K2035/124 , A61K2039/505 , C07K16/2866 , C07K16/2896 , C07K2317/622 , C07K2319/03 , C07K2319/74 , A61K2300/00
摘要： In an aspect, the present invention relates generally to the field of treating disease with CAR devices, Smart CAR devices, DE CAR devices, and/or Smart-DE CAR devices. The present invention also relates generally to the genetic modification of cytotoxic T-lymphocytes to reduce target cell killing by apoptosis and/or increase production of lytic proteins at desired times. In an aspect, the invention relates to the use of these genetically modified T-lymphocytes and/or natural killer cells with CAR devices, Smart CAR devices, DE CAR devices, and/or Smart-DE CAR devices to enhance the immune response against a disease.
摘要翻译：一方面，本发明一般涉及用CAR装置，Smart CAR装置，DE CAR装置和/或Smart-DE CAR装置治疗疾病的领域。本发明还一般涉及细胞毒性T淋巴细胞的遗传修饰以减少细胞凋亡对靶细胞的杀伤和/或在所需时间增加裂解蛋白的产生。一方面，本发明涉及将这些基因修饰的T淋巴细胞和/或天然杀伤细胞与CAR装置，Smart CAR装置，DE CAR装置和/或Smart-DE CAR装置一起用于增强对抗疾病

7. 发明申请

WO2022260968A1 COMPOSITIONS AND METHODS FOR ACTIVATING NATURAL KILLER CELLS 审中-公开
公开(公告)号：WO2022260968A1
公开(公告)日：2022-12-15
申请号：PCT/US2022/032254
申请日：2022-06-03
申请人： CHIMERA BIOENGINEERING, INC.
发明人： WANG, Benjamin , ZEINER, Gusti , ROCHE, Daniel
IPC分类号： A61K35/17 , A61K47/50 , C07K16/28 , C12N15/67
摘要： Methods and compositions for controlling transgene expression in Natural Killer Cells are disclosed. Also, disclosed are RDEs which can be used to optimize expression of transgenes in NK cells following activation pf the NK cell through a receptor, e.g., CARs or T-cell receptors. CARs and transgene payloads can also be engineered into NK cells so that the transgene payload is expressed and delivered at desired times from the NK cell. Such CAR NK cells with transgene payloads can be combined with the administration of other molecules, e.g., other therapeutics such as anticancer therapies.

8. 发明申请

WO2022086875A1 MERCURY CONTROLLED GENE EXPRESSION 审中-公开
公开(公告)号：WO2022086875A1
公开(公告)日：2022-04-28
申请号：PCT/US2021/055469
申请日：2021-10-18
申请人： CHIMERA BIOENGINEERING, INC.
发明人： WANG, Benjamin , ZEINER, Gusti
IPC分类号： A61K35/17 , C07K14/715 , C07K14/705 , A61P35/00
摘要： Control Devices are disclosed including RNA destabilizing elements (RDE) combined with transgenes, including Chimeric Antigen Receptors (CARs) in eukaryotic cells. These RDEs can be used to optimize expression of transgenes, e.g., CARs, in the eukaryotic cells so that, for example, effector function is optimized. CARs and transgene payloads can also be engineered into eukaryotic cells so that the transgene payload is expressed and delivered at desired times from the eukaryotic cell. Such CAR T-cells with transgene payloads can be combined with the administration of other molecules, e.g., other therapeutics such as anti cancer therapies.

9. 发明申请

WO2021034653A1 COMBINATION THERAPY WITH GOLD CONTROLLED TRANSGENES 审中-公开
公开(公告)号：WO2021034653A1
公开(公告)日：2021-02-25
申请号：PCT/US2020/046349
申请日：2020-08-14
申请人： CHIMERA BIOENGINEERING, INC.
发明人： WANG, Benjamin , ZEINER, Gusti , DYLLA, Scott
IPC分类号： A61K35/17 , A61K47/50 , C07K16/28 , C12N15/67 , C12N5/10 , A61K2039/5156 , A61K39/001112 , A61K39/001124 , A61K39/001129 , A61P35/00 , C07K14/7051 , C07K14/70578 , C07K14/7155 , C07K14/7156 , C07K2319/03
摘要： Control Devices are disclosed including RNA destabilizing elements (RDE) combined with transgenes, including Chimeric Antigen Receptors (CARs) in eukaryotic cells. These RDEs can be used to optimize expression of transgenes, e.g., CARs, in the eukaryotic cells so that, for example, effector function is optimized. CARs and transgene payloads can also be engineered into eukaryotic cells so that the transgene payload is expressed and delivered at desired times from the eukaryotic cell. Such CAR T-cells with transgene payloads can be combined with the administration of other molecules, e.g., other therapeutics such as anticancer therapies.

10. 发明申请

WO2017201019A1 METHODS FOR MAKING NOVEL ANTIGEN BINDING DOMAINS 审中-公开
标题翻译：制备新的抗原结合域的方法
公开(公告)号：WO2017201019A1
公开(公告)日：2017-11-23
申请号：PCT/US2017/032861
申请日：2017-05-16
申请人： CHIMERA BIOENGINEERING, INC.
发明人： WANG, Benjamin , ZEINER, Gusti
IPC分类号： A61K35/17 , A61K39/395 , A61K48/00 , C07H21/04 , C07H21/02 , C07K16/28 , C07K14/705 , C12N5/0783 , C12N5/078
摘要： The present invention relates generally to the field of making novel antigen binding domains against infectious diseases. The present invention also relates to novel CARs that utilize the novel antigen binding domains as an extracellular element. The present invention also relates to use of the novel antigen binding domains as therapeutic agents.
摘要翻译：本发明总体上涉及制备抗感染性疾病的新型抗原结合结构域的领域。本发明还涉及利用新型抗原结合结构域作为胞外元件的新型CAR。本发明还涉及新型抗原结合结构域作为治疗剂的用途。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式